» Articles » PMID: 36631484

Simplifying the Detection and Monitoring of Protein Glycosylation During in Vitro Glycoengineering

Overview
Journal Sci Rep
Specialty Science
Date 2023 Jan 11
PMID 36631484
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities. Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life. The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency. Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection. Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production. Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents. In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release. The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench. The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.

Citing Articles

Soft-sensor model development for CHO growth/production, intracellular metabolite, and glycan predictions.

Liang G, Sha S, Wang Z, Liu H, Yoon S Front Mol Biosci. 2024; 11:1441885.

PMID: 39502716 PMC: 11535473. DOI: 10.3389/fmolb.2024.1441885.


Glycosylation: mechanisms, biological functions and clinical implications.

He M, Zhou X, Wang X Signal Transduct Target Ther. 2024; 9(1):194.

PMID: 39098853 PMC: 11298558. DOI: 10.1038/s41392-024-01886-1.


Direct Glycan Analysis of Biological Samples and Intact Glycoproteins by Integrating Machine Learning-Driven Surface-Enhanced Raman Scattering and Boronic Acid Arrays.

Hu Q, Wu H ACS Meas Sci Au. 2024; 4(3):307-314.

PMID: 38910864 PMC: 11191725. DOI: 10.1021/acsmeasuresciau.4c00014.


Genetics of glycosylation in mammalian development and disease.

Stanley P Nat Rev Genet. 2024; 25(10):715-729.

PMID: 38724711 DOI: 10.1038/s41576-024-00725-x.


Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.

Orozco-Moreno M, Visser E, Hodgson K, Hipgrave Ederveen A, Bastian K, Goode E Glycobiology. 2023; 33(12):1155-1171.

PMID: 37847613 PMC: 10876042. DOI: 10.1093/glycob/cwad085.

References
1.
Ribeiro J, Mahal L . Dot by dot: analyzing the glycome using lectin microarrays. Curr Opin Chem Biol. 2013; 17(5):827-31. PMC: 3823826. DOI: 10.1016/j.cbpa.2013.06.009. View

2.
Jegouzo S, Nelson C, Hardwick T, Wong S, Lau N, Neoh G . Mammalian lectin arrays for screening host-microbe interactions. J Biol Chem. 2020; 295(14):4541-4555. PMC: 7135977. DOI: 10.1074/jbc.RA120.012783. View

3.
Lalonde M, Durocher Y . Therapeutic glycoprotein production in mammalian cells. J Biotechnol. 2017; 251:128-140. DOI: 10.1016/j.jbiotec.2017.04.028. View

4.
Kirchhoff C, Wang X, Conlon H, Anderson S, Ryan A, Bose A . Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017; 114(12):2696-2705. PMC: 5698755. DOI: 10.1002/bit.26438. View

5.
Bork K, Horstkorte R, Weidemann W . Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci. 2009; 98(10):3499-508. DOI: 10.1002/jps.21684. View